ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL24828
CHEMBL24828
Compound Name VANDETANIB
ChEMBL Synonyms ZD-64 | CAPRELSA | VANDETANIB | ZACTIMA | ZD6474 | GNF-Pf-2188
Max Phase 4 (Approved)
Trade Names CAPRELSA | ZACTIMA
Molecular Formula C22H24BrFN4O2

Additional synonyms for CHEMBL24828 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC4CCN(C)CC4
Standard InChI InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16 ...
Download InChI
Standard InChI Key UHTHHESEBZOYNR-UHFFFAOYSA-N

Sources

  • British National Formulary
  • GSK Malaria Screening
  • Novartis Malaria Screening
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • St Jude Leishmania Screening
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL24828

Molecule Features

CHEMBL24828 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Ephrin receptor inhibitor Ephrin receptor DailyMed
Epidermal growth factor receptor inhibitor Epidermal growth factor receptor DailyMed
Tyrosine-protein kinase BRK inhibitor Tyrosine-protein kinase BRK DailyMed
Tyrosine-protein kinase SRC inhibitor Tyrosine-protein kinase SRC DailyMed
Tyrosine-protein kinase TIE-2 inhibitor Tyrosine-protein kinase TIE-2 DailyMed
Tyrosine-protein kinase receptor RET inhibitor Tyrosine-protein kinase receptor RET DailyMed
Vascular endothelial growth factor receptor inhibitor Vascular endothelial growth factor receptor DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
GlioblastomaD005909EFO:0000519glioblastoma multiforme1ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials
OligodendrogliomaD009837EFO:0002501anaplastic oligodendroglioma2ClinicalTrials
Stomach NeoplasmsD013274EFO:0000178gastric carcinoma2ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma3ClinicalTrials
Carcinoma, VerrucousD018289EFO:0007535verrucous carcinoma2ClinicalTrials
Esophageal NeoplasmsD004938EFO:0002916esophageal carcinoma1ClinicalTrials
GliomaD005910EFO:0000326central nervous system cancer1ClinicalTrials
Urinary Bladder NeoplasmsD001749EFO:0000292bladder carcinoma2ClinicalTrials
AstrocytomaD001254EFO:0002499anaplastic astrocytoma2ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000181head and neck squamous cell carcinoma2ClinicalTrials
MesotheliomaD008654EFO:0000588mesothelioma2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer4ClinicalTrials
OligodendrogliomaD009837EFO:0000630oligoastrocytoma2ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma2ClinicalTrials
Ureteral NeoplasmsD014516EFO:0003844ureteral neoplasm2ClinicalTrials
Breast NeoplasmsD001943EFO:0003869breast neoplasm2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0002890renal carcinoma2ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma2ClinicalTrials
GliosarcomaD018316EFO:1001465gliosarcoma2ClinicalTrials
Head and Neck NeoplasmsD006258EFO:0006859head and neck malignant neoplasia2ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma2ClinicalTrials
Thyroid NeoplasmsD013964EFO:0002892thyroid carcinoma4ClinicalTrials
DailyMed
NeuroblastomaD009447EFO:0000621neuroblastoma1ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma2ClinicalTrials
Colorectal NeoplasmsD015179EFO:0000365colorectal adenocarcinoma2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma2ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000349clear cell renal carcinoma2ClinicalTrials
Gastrointestinal Stromal TumorsD046152Orphanet:44890Gastrointestinal stromal tumor2ClinicalTrials
Thyroid NeoplasmsD013964EFO:0003841thyroid neoplasm4ClinicalTrials
Urethral NeoplasmsD014523EFO:0003846urethral neoplasm2ClinicalTrials
Ovarian NeoplasmsD010051EFO:0001075ovarian carcinoma1ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma2ClinicalTrials
Small Cell Lung CarcinomaD055752EFO:0000702small cell lung carcinoma2ClinicalTrials

Clinical Data

ClinicalTrials.gov VANDETANIB
The Cochrane Collaboration VANDETANIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL24828. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL203 Epidermal growth factor receptor erbB1 Homo sapiens 1.000
CHEMBL5147 Ephrin type-B receptor 4 Homo sapiens 1.000
CHEMBL2068 Ephrin type-A receptor 2 Homo sapiens 1.000
CHEMBL279 Vascular endothelial growth factor receptor 2 Homo sapiens 1.000
CHEMBL1868 Vascular endothelial growth factor receptor 1 Homo sapiens 1.000
CHEMBL1824 Receptor protein-tyrosine kinase erbB-2 Homo sapiens 1.000
CHEMBL3009 Receptor protein-tyrosine kinase erbB-4 Homo sapiens 1.000
CHEMBL2041 Tyrosine-protein kinase receptor RET Homo sapiens 1.000
CHEMBL267 Tyrosine-protein kinase SRC Homo sapiens 1.000
CHEMBL1955 Vascular endothelial growth factor receptor 3 Homo sapiens 0.997
CHEMBL4718 MAP kinase-interacting serine/threonine-protein kinase MNK1 Homo sapiens 0.997
CHEMBL4355 Serine/threonine-protein kinase GAK Homo sapiens 0.971
CHEMBL1913 Platelet-derived growth factor receptor beta Homo sapiens 0.947
CHEMBL2185 Serine/threonine-protein kinase Aurora-B Homo sapiens 0.747
CHEMBL6191 SPS1/STE20-related protein kinase YSK4 Homo sapiens 0.545
CHEMBL3905 Tyrosine-protein kinase Lyn Homo sapiens 0.454
CHEMBL4202 Serine/threonine-protein kinase 2 Homo sapiens 0.395
CHEMBL4948 Dual specificity mitogen-activated protein kinase kinase 5 Homo sapiens 0.336
CHEMBL2250 Tyrosine-protein kinase BLK Homo sapiens 0.271
CHEMBL3587 Dual specificity mitogen-activated protein kinase kinase 1 Homo sapiens 0.229



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL203 Epidermal growth factor receptor erbB1 Homo sapiens 1.000
CHEMBL2068 Ephrin type-A receptor 2 Homo sapiens 1.000
CHEMBL5147 Ephrin type-B receptor 4 Homo sapiens 1.000
CHEMBL1824 Receptor protein-tyrosine kinase erbB-2 Homo sapiens 1.000
CHEMBL279 Vascular endothelial growth factor receptor 2 Homo sapiens 1.000
CHEMBL1868 Vascular endothelial growth factor receptor 1 Homo sapiens 1.000
CHEMBL3009 Receptor protein-tyrosine kinase erbB-4 Homo sapiens 1.000
CHEMBL2041 Tyrosine-protein kinase receptor RET Homo sapiens 1.000
CHEMBL1913 Platelet-derived growth factor receptor beta Homo sapiens 1.000
CHEMBL267 Tyrosine-protein kinase SRC Homo sapiens 1.000
CHEMBL1955 Vascular endothelial growth factor receptor 3 Homo sapiens 1.000
CHEMBL2634 Tyrosine-protein kinase CSK Homo sapiens 1.000
CHEMBL4718 MAP kinase-interacting serine/threonine-protein kinase MNK1 Homo sapiens 0.999
CHEMBL3587 Dual specificity mitogen-activated protein kinase kinase 1 Homo sapiens 0.996
CHEMBL4355 Serine/threonine-protein kinase GAK Homo sapiens 0.996
CHEMBL4948 Dual specificity mitogen-activated protein kinase kinase 5 Homo sapiens 0.992
CHEMBL3650 Fibroblast growth factor receptor 1 Homo sapiens 0.982
CHEMBL6191 SPS1/STE20-related protein kinase YSK4 Homo sapiens 0.980
CHEMBL5260 Serine/threonine-protein kinase TNNI3K Homo sapiens 0.975
CHEMBL4202 Serine/threonine-protein kinase 2 Homo sapiens 0.975

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
475.4 474.1067 5 6 59.51 BASE


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 1 1 6 1 1


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- 8.92 4 2.5 3 30 0.54

Structural Alerts

There are 2 structural alerts for CHEMBL24828. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE12 - vandetanib

ChemSpider ChemSpider:UHTHHESEBZOYNR-UHFFFAOYSA-N
DailyMed vandetanib
PubChem SID: 103905338 SID: 124893338 SID: 144206064 SID: 170465617 SID: 50100123 SID: 50112766
Wikipedia Vandetanib

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL24828



ACToR 443913-73-3 338992-00-0
BindingDB 21
Brenda 127382
ChEBI 49960
ChemicalBook CB01011762
DrugBank DB05294
DrugCentral 4178
eMolecules 10778617
EPA CompTox Dashboard DTXSID1046681
FDA SRS YO460OQ37K
Guide to Pharmacology 5717
IBM Patent System B9C60195205D28B2A3915B98497B5F93
LINCS LSM-1199
Mcule MCULE-4705827953
MolPort MolPort-005-942-399
Nikkaji J1.720.281B
PDBe ZD6
PharmGKB PA166118341
PubChem 3081361
PubChem: Drugs of the Future 12015522
PubChem: Thomson Pharma 14761077
Selleck Vandetanib
SureChEMBL SCHEMBL9044
ZINC ZINC000053683345

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/UHTHHESEBZOYNR-UHFFFAOYSA-N spacer
spacer